Compare ATPC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATPC | PPCB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Malaysia | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.2M |
| IPO Year | 2017 | N/A |
| Metric | ATPC | PPCB |
|---|---|---|
| Price | $2.25 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 04-06-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,322,747.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.05 | $0.11 |
| 52 Week High | $6.30 | $10.69 |
| Indicator | ATPC | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 28.08 |
| Support Level | $1.28 | N/A |
| Resistance Level | $2.55 | $0.40 |
| Average True Range (ATR) | 0.60 | 0.02 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 11.34 | 7.02 |
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.